Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market

Jul 20 2016

• By Donna Young

Related Content

Apotex biosimilar of Amgen's Neulasta under FDA review

Dec 18 2014

Apotex 2nd biosimilar under FDA review; seeks filgrastim OK

Feb 18 2015

Novartis/Sandoz make history with 1st US biosimilar Zarxio

Mar 07 2015

Tentative-Style Approvals Coming For US Biosimilars?

Jul 06 2016

Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No

Jul 19 2016

Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts

Apr 06 2016

1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing

Sep 03 2015

Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA

Jul 19 2016

Related Companies

Novartis AG

Amgen, Inc.

Novartis AG

Pfizer Inc.

Celltrion, Inc.

Additional Topics

United States Companies Biosimilars Policy Approvals Commercial Regulation Market Access

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window